Efficacy, retention rate and safety of adalimumab treatment in patients with non-infectious uveitis and scleritis: a real-world, retrospective, single-centre study-Reference-Cited by-同舟云学术

Efficacy, retention rate and safety of adalimumab treatment in patients with non-infectious uveitis and scleritis: a real-world, retrospective, single-centre study

Published:2023-10-26 Issue: Volume: Page:
ISSN:0950-222X
Container-title:Eye
language:en
Short-container-title:Eye

Author:

Çam Furkan^ORCID,Celiker Hande

Publisher

Springer Science and Business Media LLC

Subject

Ophthalmology

Link

https://www.nature.com/articles/s41433-023-02800-9.pdf

Reference33 articles.

1. Moudgil KD, Choubey D. Cytokines in autoimmunity: role in induction, regulation, and treatment. J Interferon Cytokine Res. 2011;31:695–703. https://doi.org/10.1089/jir.2011.0065.

2. Jaffe GJ, Dick AD, Brézin AP, Nguyen QD, Thorne JE, Kestelyn P. et al. Adalimumab in Patients with Active Noninfectious Uveitis. N Engl J Med. 2016;375:932–43. https://doi.org/10.1056/NEJMoa1509852.

3. Santos Lacomba M, Marcos Martín C, Gallardo Galera JM, Gómez Vidal MA, Collantes Estévez E, Ramírez Chamond R. et al. Aqueous humor and serum tumor necrosis factor-alpha in clinical uveitis. Ophthalmic Res. 2001;33:251–5. https://doi.org/10.1159/000055677.

4. Sharma SM, Damato E, Hinchcliffe AE, Andrews CD, Myint K, Lee R. et al. Long-term efficacy and tolerability of TNFα inhibitors in the treatment of non-infectious ocular inflammation: an 8-year prospective surveillance study. Br J Ophthalmol. 2021;105:1256–62. https://doi.org/10.1136/bjophthalmol-2018-312767.

5. Durrani K, Kempen JH, Ying GS, Kacmaz RO, Artornsombudh P, Rosenbaum JT. et al. Adalimumab for Ocular Inflammation. Ocul Immunol Inflamm. 2017;25:405–12. https://doi.org/10.3109/09273948.2015.1134581.

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Treatment of Behçet Uveitis in Türkiye;Turkish Journal of Ophthalmology;2024-08-29